Erin Mistry compensation by year
CorMedix Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $389,577 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $694,200 |
| Non-equity incentive | $156,800 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $1,240,577 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CorMedix Inc. DEF 14A filed October 8, 2024, accession 0001213900-24-086301, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CorMedix Inc. filed document, accession 0001213900-24-086301. Every figure is read from that document and cited to the page and table it appears in. Filed October 8, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 2,500 | — | $3.57 |
| Option | 10,500 | — | $4.03 |
| Option | 2,500 | — | $8.32 |
| Option | 60,000 | — | $5.45 |
| Option | 150,000 | — | $4.43 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CorMedix Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
4 Form 4 lines since the FY2023 proxy (filed October 8, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-01-10 | Tax withholding | — | 5,689 | $11.19 | 100,992 |
| 2025-01-02 | Grant or award | — | 62,500 | $0.00 | 114,511 |
| 2025-01-02 | Tax withholding | — | 7,830 | $8.22 | 106,681 |
| 2024-10-31 | Purchase | — | 1,500 | $9.99 | 52,011 |
The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
CorMedix’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Joseph Todisco | Chief Executive Officer | $2,459,342 |
| Phoebe Mounts | Former Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal | $1,254,582 |
| Erin Mistry · this page | Executive Vice President and Chief Commercial Officer | $1,240,577 |
| Matthew David | Chief Financial Officer | $1,031,150 |
The full CorMedix compensation record
free company briefThis page is one person within CorMedix's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CorMedix's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.